[ Price : $8.95]
FDA posts a draft guidance on biosimilar development formal meetings between the agency and sponsors.[ Price : $8.95]
PhRMA tells FDA it strongly agrees with the potential benefits of artificial intelligence and machine learning, among three other ...[ Price : $8.95]
Novartis says top-line data from two Phase 3 studies evaluating remibrutinib 25 mg in patients with chronic spontaneous urticaria ...[ Price : $8.95]
Federal Register notice: FDA seeks comments on an information collection entitled Time and Extent Applications for Nonprescription...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled QTc Information in Human Prescription Drug and Biological P...[ Price : $8.95]
Aspen says it will start a Phase 1/2a trial of its ANPD001 cell therapy to treat Parkinsons disease under an FDA-approved IND.[ Price : $8.95]
FDA accepts for review a Vitaris/Mapi ANDA for GA Depot 40 mg as a once-monthly injection to treat relapsing multiple sclerosis.[ Price : $8.95]
A Health Affairs article calls on doctors and health systems to take steps to test generic drugs to minimize risks to patients.